Skip to content

Repetitive Transcranial Magnetic Stimulation

Study of efficasy and effect prediction of Repetitive Transcranial Magnetic Stimulation in psychiatric disorder. - rTMS

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-jRCTs042180154
Enrollment
50
Registered
2019-03-29
Start date
2015-09-07
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Mental disorder with depressive state

Interventions

Repetitive transcranial magnetic stimulation (rTMS) is performed.

Sponsors

Kawasaki Yasuhiro
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Patients who has diagnosis of depressed disorder group, bipolar disorder and related disorder group, schizophrenia spectrum disorder and other psychiatric disorder group, anxiety group, obsessive compulsive disorder and related group, psychic trauma and stress causation disorder group, dissociation group, somatic symptom and related group, eating behavior disorder and eating disorder group, excretion group, personality disorder group. 2. Patients who will be able to obtain written informed consent. 3. Age of 20 to 80 years.

Exclusion criteria

Exclusion criteria: 1. Patients who have received rTMS therapy in the past. 2. Patients who presents bvious dementia, depressive state of organic or symptomatic. 3. Patients whose symptoms have improved to the extent that they can be reinstated. 4. Patients who show severe episodes accompanied by psychotic symptoms, impending dilapidation thought or symptoms of tension, and symptoms recommended for electroconvulsive therapy. 5. Patients who have metal indwelling in the cranium or who have a pacemaker implanted in the heart. 6. Patients who have had a history of drug abuse. 7. Patients who have severe mental retardation. 8. Pregnant woman. 9. Patients who was considered ineligible by investigators.

Design outcomes

Primary

MeasureTime frame
Evaluation of improvement in depressive state by POMS and HAM-D.

Secondary

MeasureTime frame
Frontal cerebral blood flow by NIRS. Volume evaluation of amygdala body by MRI.

Contacts

Public ContactYasuhiro Kawasaki

Kanazawa Medical University Hospital

kawasaki@kanazawa-med.ac.jp+81-76-286-3511

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026